Skip to Content
Biotechnology

Getting your genome sequenced might not make you spend more on health care

March 22, 2018

Geneticists at Brigham and Women’s Hospital in Boston found that genome sequencing, a type of test that provides a full readout of your DNA, didn’t significantly increase health-care spending in the short term.

Sequencing for everyone? As genome sequencing gets cheaper and becomes more widely available, a major concern has been whether it will make people use more health services. Returning detailed genetic results to healthy people could make them seek out medical tests, screenings, or preventive procedures that they otherwise wouldn’t have gotten—and that they might not need.

The cost question: Among 100 patients with a known heart problem, the Boston team found that the average cost of health care over six months was $8,109 for those who had received genome sequencing and $9,670 for those who didn’t get the test. For 100 primary-care patients who were “ostensibly healthy,” average costs were slightly higher in the group that got sequenced—$3,670 versus $2,989. The researchers say those differences weren’t statistically significant, because costs varied a lot among individuals.

The caveat: The researchers only looked at health-care costs over a six-month period. That may be too short a time frame to understand how genome sequencing will affect health-care spending over the long run.

Deep Dive

Biotechnology

Sam Altman invested $180 million into a company trying to delay death

Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.

Forget designer babies. Here’s how CRISPR is really changing lives

The gene-editing tool is being tested in people, and the first treatment could be approved this year.

More than 200 people have been treated with experimental CRISPR therapies

But at a global genome-editing summit, exciting trial results were tempered by safety and ethical concerns.

Three-parent baby technique could create babies at risk of severe disease

The approach was designed to prevent mitochondrial disease, but new evidence shows it might not work as planned.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.